Major shifts in the treatment and prognosis of prostate cancer due to changes in pathological diagnosis and grading.
about
Overexpression of RAD51 occurs in aggressive prostatic cancerIdentification of miRs-143 and -145 that is associated with bone metastasis of prostate cancer and involved in the regulation of EMTPathology in prostate research: optimizing the pathological data.Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT studyPrognostic Gleason grade grouping: data based on the modified Gleason scoring system.Clinical Validation of the 2005 ISUP Gleason Grading System in a Cohort of Intermediate and High Risk Men Undergoing Radical ProstatectomyWhat is the risk posed by prostate cancer?Prostate cancer in male BRCA1 and BRCA2 mutation carriers has a more aggressive phenotypeGleason score and lethal prostate cancer: does 3 + 4 = 4 + 3?Hsp-27 expression at diagnosis predicts poor clinical outcome in prostate cancer independent of ETS-gene rearrangementInteractive digital slides with heat maps: a novel method to improve the reproducibility of Gleason grading.Do adenocarcinomas of the prostate with Gleason score (GS) ≤6 have the potential to metastasize to lymph nodes?The value of second-opinion pathology diagnoses on prostate biopsies from patients referred for management of prostate cancer.The reasons behind variation in Gleason grading of prostatic biopsies: areas of agreement and misconception among 266 European pathologists.The value of the 2005 International Society of Urological Pathology (ISUP) modified Gleason grading system as a predictor of biochemical recurrence after radical prostatectomy.Targeted prostate cancer screening in men with mutations in BRCA1 and BRCA2 detects aggressive prostate cancer: preliminary analysis of the results of the IMPACT study.Biopsy undergrading in men with Gleason score 6 and fatal prostate cancer in the European Randomized study of Screening for Prostate Cancer Rotterdam.Prostate cancer incidence, clinical stage and survival in relation to obesity: a prospective cohort study in Denmark.Neuroendocrine differentiation does not have independent prognostic value in conservatively treated prostate cancer
P2860
Q28267299-3B28A74C-2F04-487A-9AFE-39253356CC1EQ28744173-4FB5193B-9982-479E-9949-D89B037BA8F1Q33909029-0E6FFDF6-2C3F-40EA-B57C-890ECFB7FA58Q33927384-E1363175-CBED-4E1E-BED1-6B6DAADEE887Q34610101-0FBA6504-87F6-445A-93B0-420DC150BDACQ35885756-5109D05C-1C8A-4669-8E28-5075A4854CF4Q36520479-B8FE447D-44B4-4000-9FA1-221D265D8547Q36614710-35DB5C5D-285D-4C70-B950-555ED17CE4A2Q37280719-D000B5D4-83E7-4F72-94B4-D91D5F2F8DB7Q37400523-214E95F8-E6C8-4B68-BE83-3CF052A3828BQ37893527-8FF92C0B-1B6F-4F81-BD5B-FD1AB185F517Q38005257-6E74F859-CF16-4BB6-8289-AB2205AB3EFEQ42781094-31CF6951-7EDB-4CC1-8E61-DADADD55E76EQ44345074-4592274E-C683-4FD9-BAF6-1B4EA3B9477EQ44708760-EB41FB65-95B9-4472-A7F6-53B45E21FFE0Q46935108-B4D071F0-F137-44A5-9E14-F6FE9FCE8FEBQ48701068-DDD1BEBD-BF11-4897-99A0-E2FFAA2EE5F6Q50562635-E780438E-4D40-48DE-B489-15E361B25D6FQ58327426-BCACB796-0A3E-4A86-886E-A78F08E77CF4
P2860
Major shifts in the treatment and prognosis of prostate cancer due to changes in pathological diagnosis and grading.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Major shifts in the treatment ...... logical diagnosis and grading.
@en
type
label
Major shifts in the treatment ...... logical diagnosis and grading.
@en
prefLabel
Major shifts in the treatment ...... logical diagnosis and grading.
@en
P2093
P2860
P1433
P1476
Major shifts in the treatment ...... ological diagnosis and grading
@en
P2093
Christopher S Foster
Daniel M Berney
Gabrielle Fisher
Jack Cuzick
James Eastham
Michael W Kattan
Paul Fearn
Peter Scardino
R Timothy D Oliver
Trans-Atlantic Prostate Group
P2860
P304
P356
10.1111/J.1464-410X.2007.07199.X
P577
2007-12-01T00:00:00Z